Marlene Haffner
Vorstandsvorsitzender bei Haffner Associates LLC
Profil
Marlene Haffner is currently the Chief Executive Officer at Haffner Associates LLC, and also holds director positions at viDA Therapeutics, Inc., DeNovaMed, Inc., and is a Professor at Uniformed Services University of the Health Sciences.
Previously, she was the Director-Global Regulatory Policy & Intelligence at Amgen, Inc., an Independent Director at Bioblast Pharma Ltd., and the Director-Office of Orphan Products Development at the US Food & Drug Administration.
She holds a doctorate from George Washington University and a graduate degree from Johns Hopkins Bloomberg School of Public Health.
Aktive Positionen von Marlene Haffner
Unternehmen | Position | Beginn |
---|---|---|
Haffner Associates LLC | Vorstandsvorsitzender | 01.01.2009 |
Uniformed Services University of the Health Sciences | Corporate Officer/Principal | - |
DeNovaMed, Inc.
DeNovaMed, Inc. Pharmaceuticals: MajorHealth Technology DeNovaMed, Inc. develops an antibiotic to treat infections caused by drug-resistant bacteria or superbugs. It focuses in the areas of Gram-positive infections, methicillin-resistant Staph and vancomycin-resistant Enterococcus pose a threat to patients in hospitals and community health facilities by producing skin, wound and systemic infections. The firm also has an ongoing discovery program for Gram-negative adjuvants, which can improve the efficacy of older antibacterial. The company was founded by Donald F. Weaver, Christopher R. McMaster and David Byers in 2006 and is headquartered in Halifax, Canada. | Direktor/Vorstandsmitglied | - |
viDA Therapeutics, Inc.
viDA Therapeutics, Inc. BiotechnologyHealth Technology viDA Therapeutics, Inc. operates as a biotechnology company. It offers discovery, development and commercialization of novel and targeted therapeutics for the treatment of inflammatory and age related diseases. The firm's discovery platform is based on novel research regarding a distinctly different and recently identified, extracellular role for granzymes in the destruction and inflammation of tissues. The company was founded by Alistair Duncan Jr. and David Granville in 2008 and is headquartered in Vancouver, Canada. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Marlene Haffner
Unternehmen | Position | Ende |
---|---|---|
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Direktor/Vorstandsmitglied | 31.07.2018 |
AMGEN INC. | Corporate Officer/Principal | 01.01.2009 |
US Food & Drug Administration
US Food & Drug Administration General GovernmentGovernment US Food & Drug Administration operates agencies to protect health and human services. It protects and promotes public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices, cosmetics, animal foods and feed and veterinary products. The company was founded by Theodore Roosevelt and Harvey Washington Wiley on 30th June, 1906 and is headquartered in Silver Spring, MD. | Corporate Officer/Principal | 01.01.2007 |
Ausbildung von Marlene Haffner
Johns Hopkins Bloomberg School of Public Health | Graduate Degree |
George Washington University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
AMGEN INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Health Technology |
Haffner Associates LLC | |
DeNovaMed, Inc.
DeNovaMed, Inc. Pharmaceuticals: MajorHealth Technology DeNovaMed, Inc. develops an antibiotic to treat infections caused by drug-resistant bacteria or superbugs. It focuses in the areas of Gram-positive infections, methicillin-resistant Staph and vancomycin-resistant Enterococcus pose a threat to patients in hospitals and community health facilities by producing skin, wound and systemic infections. The firm also has an ongoing discovery program for Gram-negative adjuvants, which can improve the efficacy of older antibacterial. The company was founded by Donald F. Weaver, Christopher R. McMaster and David Byers in 2006 and is headquartered in Halifax, Canada. | Health Technology |
US Food & Drug Administration
US Food & Drug Administration General GovernmentGovernment US Food & Drug Administration operates agencies to protect health and human services. It protects and promotes public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices, cosmetics, animal foods and feed and veterinary products. The company was founded by Theodore Roosevelt and Harvey Washington Wiley on 30th June, 1906 and is headquartered in Silver Spring, MD. | Government |
viDA Therapeutics, Inc.
viDA Therapeutics, Inc. BiotechnologyHealth Technology viDA Therapeutics, Inc. operates as a biotechnology company. It offers discovery, development and commercialization of novel and targeted therapeutics for the treatment of inflammatory and age related diseases. The firm's discovery platform is based on novel research regarding a distinctly different and recently identified, extracellular role for granzymes in the destruction and inflammation of tissues. The company was founded by Alistair Duncan Jr. and David Granville in 2008 and is headquartered in Vancouver, Canada. | Health Technology |